Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 switch study of doravirine/islatravir versus continued BIC/FTC/TAF in virologically suppressed adults with HIV-1
MOH_2023-01-18_012276Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Switch to doravirine + islatravir with Continue BIC/FTC/TAF (2 arms). Started Jan 2023; status: active, not recruiting.
02
Drugs
doravirineislatravirbictegraviremtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on MOH_2023-01-18_012276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-18_012276.